HIGH

Dr. Reddy's Succinylcholine Chloride Injection Recall 2025 — 571 Vials Over OOS Preservative Drop

Dr. Reddy's Laboratories Inc. recalled 571 vials of Succinylcholine Chloride Injection, USP nationwide in the United States. The recall cites an out-of-specification result during six-month stability testing due to decreased preservative concentration. Healthcare providers and patients should stop using the product immediately and await guidance from the recall letter.

Quick Facts at a Glance

Recall Date
September 26, 2025
Hazard Level
HIGH
Brands
Succinylcholine, Dr. Reddy's Laboratories
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL

Hazard Information

Out-of-Specification (OOS) result during the 6-month stability testing; decreased preservative concentration.

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Dr. Reddy's Laboratories, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Succinylcholine Chloride Injection is a short-acting neuromuscular blocker used to facilitate intubation and muscle relaxation during surgery. The product is distributed in multi-dose vials for hospital and clinical use.

Why This Is Dangerous

The product showed an out-of-specification result in six-month stability testing, specifically a decrease in preservative concentration. This can raise concerns about sterility and potency of the injectable medication.

Industry Context

This recall is not described as part of a broader industry pattern in the notice.

Real-World Impact

Hospitals and surgical teams may need to identify alternative neuromuscular blocking agents and adjust procurement to replace the recalled lots.

Practical Guidance

How to identify if yours is affected

  1. Check NDC 43598-666-25 on the vial label.
  2. Verify Lot number K250048 on the packaging.
  3. Confirm quantity on hand is 571 vials.

Where to find product info

Recall letters and identification details are available via the FDA recall page linked in the notice.

What timeline to expect

Replacement or discard instructions will be provided in the recall letter; typical recall timelines include weeks to months depending on facility.

If the manufacturer is unresponsive

  • Escalate to hospital risk management or the medical affairs liaison for Dr. Reddy's Laboratories.
  • Contact the FDA recall enforcement line if the company is unresponsive.

How to prevent similar issues

  • Implement strict lot-level quarantine procedures for all recalled products.
  • Verify NDC and lot numbers during receiving to prevent mix-ups with non-recalled lots.
  • Maintain an updated recall contact list for vendors and suppliers.

Documentation advice

Keep the recall letter, FDA notice, and correspondence with the distributor. Photograph and log the recalled lot and its disposition.

Product Details

NDC 43598-666-25. Lot K250048. 25 x 10 mL multiple-dose vials. 200 mg/10 mL (20 mg/mL). For intravenous or intramuscular use. Rx Only. Distributed nationwide by Dr. Reddy's Laboratories Inc., Princeton, NJ 08540.

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 571 vials recalled
  • NDC 43598-666-25
  • Lot K250048
  • 6-month stability testing with out-of-specification result
  • Distributor: Dr. Reddy's Laboratories Inc.
  • Nationwide distribution in the USA

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
8/ 10
Affected Groups
GENERAL
Injury Types
POISONINGLACERATIONELECTRICALOTHER

Product Classification

Product Details

Model Numbers
K250048
UPC Codes
43598-666
43598-666-11
43598-666-25
Affected States
ALL
Report Date
October 15, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more
Vehicles & Parts
HIGH

Chrysler Pacifica Radio Recall 2025 Over Rearview Camera Display Issue

Chrysler is recalling 2024-2025 Pacifica minivans after a radio installed during production could fail to display the rearview camera image. Dealers will replace the radio at no cost. Owner letters were mailed August 7, 2025. Contact Chrysler customer service at 800-853-1403 for details.

Chrysler
A rearview
Read more